Guest
Guest
Dec 06, 2025
2:24 AM
|
It’s difficult to point to an exact date when Tadalista 40 mg — or more broadly its active drug Tadalafil — reached its “popularity peak.” But we can look at historical milestones and usage trends to identify approximate high points.
Tadalafil (marketed under names like Cialis, and generically as Tadalista) was first approved in 2003.
By 2005, Cialis had become a “blockbuster” drug, achieving over US$1?billion globally in sales.
In 2005, in France for instance, Cialis overtook its main rival as the top-selling erectile?dysfunction treatment, indicating strong uptake in that period.
More recently, data show that prescriptions for PDE?5 inhibitors overall — and tadalafil in particular — increased between 2014 and 2024. In that period, tadalafil became the most frequently continued therapy among ED medications, overtaking others.
These facts suggest that the mid?2000s (roughly 2004–2006) might represent the first widespread “boom” or peak in popularity for tadalafil-based treatments which would include TADALISTA 40 MG. Then, another long-term rise occurred over 2010s–2020s as tadalafil consolidated its place as the leading PDE?5 inhibitor — meaning a more gradual “peak period” rather than a sharp spike.
Because “popularity” depends on many factors (prescription frequency, market availability, social acceptance, generic competition, etc.), there’s no single globally uniform peak. In some countries the high?adoption phase was early (mid-2000s), while in others the growth may have been more recent.
|
